Drug Trial Radar · NCT07862465
Medical Access Program for Valemetostat Tosylate (DS 3201b) For The Treatment of Patients With Relapsed/Refractory (R/R) Peripheral T-cell Lymphoma (PTCL)
Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Available
Enrollment
Not stated
Start
Not stated
Primary completion
Not stated
Sponsor
- Lead sponsor
- Daiichi SankyoDaiichi Sankyo (DSNKY)
- Sponsor type
- Industry
- First posted
- Oct 7, 2026
Design
- Study type
- Expanded access
- Who can join
- All sexes, from 18 years
Summary
As written by the sponsor on the registry.
Valemetostat tosylate demonstrates antitumour activity in patients with peripheral T-cell lymphomas (PTCL) with a manageable safety profile. This Medical Access Program (MAP) offers an alternative treatment option for patients with PTCL who are ineligible for clinical trials by providing access to valmetostat tosylate, a medicinal product that has received marketing authorisation in Japan.
Conditions
- Peripheral T-cell Lymphomas
- Adult T-cell Leukemia/Lymphoma
- Anaplastic Large Cell Lymphoma
- Refractory Nodal T-follicular Helper Lymphoma
Interventions
Valemetostat tosylateDrug
In this MAP, the recommended starting dose for eligible patients is 200 mg of valemetostat tosylate once daily in continuous 28-day cycles, to be continued until disease progression or unacceptable toxicity.
Primary outcomes
What the sponsor says the trial is designed to measure.
No primary outcomes listed.
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.